Administration of estrogen to cholesterol-fed rabbits dramatically retarded arterial lesion development despite its lack of effect on plasma cholesterol concentration and on llpoprotein patterns. Cholesteryl ester influx into the aortic wall was also much lower in the estrogen-treated animals and paralleled the aortic cholesterol content in treated and untreated animals; the fraction of aortic cholesteryl ester lost by efflux was the same in treated and untreated animals. The fraction of newly entered cholesteryl ester hydrolyzed by aorta was significantly reduced In the estrogen-treated animals. Low cholesteryl ester Influx and relatively less hydrolysis of cholesteryl ester by the aorta may be indicative of reduced Internallzatlon of plasma cholesteryl ester by aortic cells, which may in turn account for the reduced atherogenesis in the estrogen-treated rabbits. (Arteriosclerosis 6
I t has been well documented that premenopausal women have a lower incidence of heart disease than men. Ovariectomy and menopause cause the loss of this "resistance" to coronary events, 12 and estrogens have been thought to provide this "protective" effect. 3 Kushwaha and Hazzard 4 have shown that estrogen retards the development of atherosclerosis in cholesterol-fed rabbits. They attribute this to a lowering of the plasma cholesterol levels, in particular the very low density lipoprotein fraction. However, others have found that estrogen may have a protective effect without any alterations in plasma cholesterol levels. 56 Estrogen administration has also been shown to alter aortic enzyme activities, 78 to inhibit increased arterial collagen and elastin, a 10 to enhance prostacyclin synthesis, 11 and to alter platelet aggregation. 1213 Therefore, estrogen may act directly on the arterial wall, possibly mediated by estrogen receptors thought to be present in arterial tissue. 14 " 19 Subbiah 7 has reported that the adminis-tration of estrogen to atherosclerosis-susceptible White Carneau pigeons increased the activity of arterial lysosomal cholesteryl ester hydrolase and decreased the activity of cholesteryl ester synthetase when these enzymes were measured in vitro. Others have reported 6 that after the administration of estrogens to pigeons with pre-existing arterial lesions, their arteries contained relatively less lipid material than did the arteries from the untreated group. These studies suggest that, in addition to alterations in plasma cholesterol levels, estrogen may retard atherogenesis by altering the lipid metabolism of the arterial wall.
The present study reports that estrogen retards atherogenesis with no effect on the plasma cholesterol levels in the cholesterol-fed rabbit. The effects of estrogen administration on the influx and metabolism of cholesteryl ester in the aortas of cholesterolfed rabbits in vivo are also reported.
Methods

Animals
All rabbits were female New Zealand Whites from either Dutchland Laboratories, Denver, Pennsylvania, or Beckens Research Animal Farm, Sanborn, New York. All rabbits were housed individually in a controlled environment with a 12-hour light cycle. One group of rabbits was fed daily 100 g of Purina Rabbit Laboratory Chow supplemented with 0.5 g cholesterol (Nutritional Biochemical Company, Cleveland, Ohio) and 2.5 g Wesson oil (Hunt Wes-son Foods, Incorporated, Fullerton, California) for 8 weeks. A second group of rabbits was fed the same diet supplemented with 0.2 g cholesterol and 2.0 g Wesson oil for 33 weeks. Within each group, animals were divided into treated and untreated subgroups. Treated animals from each group received weekly intramuscular injections of 0.5 mg/kg body weight of 17-estradiol cypionate (Med-tech, Incorporated, Elwood, Kansas) in cottonseed oil. Untreated animals received only cottonseed oil. The plasma cholesterol levels of both groups were monitored during the entire cholesterol-feeding period. Experimental protocols were approved according to University guidelines.
Radlolabeled Compounds
1,2(n)-3 H:-cholesterol (54 Ci/nmol) and 4-14 C-cholesterol (58.4 mCi/nmol) were purchased from Amersham/Searle Corporation and cholesteryl 1-14 Coleate from New England Nuclear (Boston, Massachusetts). 3 H-and u C-cholesteryl oleate and 3 H-, 14 C-cholesteryl oleyl ether were synthesized and purified as described in the preceding paper. 20
Experimental Procedure
Plasma was labeled by incubation with egg phosphatidylcholine (Lipid Products, South Nutfield, England) vesicles containing radioactive cholesteryl oleoyl ester and cholesteryl oleyl ether as described previously. 20 " 22 The experimental procedure was the same as that described elsewhere 20 with the following additions: plasma from the group of rabbits on the 0.5% cholesterol diet was labeled with 3 H-cholesteryl oleyl ether and 14 C-cholesteryl oleate. Plasma from the group on 0.2% cholesterol diet was labeled with 14 C-cholesteryl oleyl ether, 3 H-cholesteryl oleate, and cholesteryl 14 C-oleate. The second group of rabbits was also injected intravenously with autologous, ^l esteryl oleyl ether-labeled plasma 25 days before the end of the experiment. The amounts of the aortas covered with lesions and lesion thickness were determined visually. Grades of 0 to 5 were assigned by three observers, two of whom were unaware of sample sources. The three independent judgments were averaged for each artery. Lipid analyses were the same as those described in our companion paper. 20 Calculation of cholesteryl ester influx and hydrolysis were the same as described previously. 20 Except where indicated, Student's /test was used for statistical analysis of the data.
Results
In the first experiment, rabbits were fed 0.5% cholesterol for 8 weeks. All animals consumed 100 g of diet per day, and the weight gained during the experimental period was the same for estrogen-treated and untreated rabbits ( Table 1 ). Dietary cholesterol supplementation produced a rapid rise in plasma cholesterol, which appeared to level off after 6 weeks on the diet (Figure 1 ). Plasma cholesterol levels of the estrogen-treated and untreated rabbits were similar during the entire experimental period ( Figure 1 ). The distribution of cholesterol into the various lipoprotein fractions also did not differ significantly (f test, p > 0.05) between treated and untreated animals (Table 1 ). In addition to the t test to detect significant differences in cholesterol levels between treated and untreated animals, group regression analysis indicated that there were no significant differences in the slopes or intercepts for the different lipoprotein fractions from treated and untreated animals. This contrasts with the report of Kushwaha and Hazzard 4 who observed that in rabbits fed 0.2% cholesterol, 17-estradiol cypionate decreased plasma cholesterol levels by preventing the increase of d < 1.019 plasma lipoproteins seen in the untreated, cholesterol-fed rabbits. The plasma levels of low 
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Values are means ± standard error. Number of rabbits is given in parentheses. density and high density lipoproteins did not differ significantly in the treated and untreated animals.
To duplicate these conditions, we fed a second group of rabbits a diet supplemented with only 0.2% cholesterol. The treated group received the same amount of estrogen as in our first experiment and in the experiment of Kushwaha and Hazzard. Figure 2 shows that the plasma cholesterol levels were similar for the treated and untreated rabbits during the 33-week experimental period. The distribution of cholesterol between d < 1.019 and d > 1.019 plasma lipoproteins also did not differ significantly between treatment groups after 22 or 33 weeks ( Table  2 ). The discrepancy between the present results and those reported by Kushwaha and Hazzard 4 cannot be readily explained. In neither study did we observe any differences in feed consumption or body weight. Moreover, Kushwaha and Hazzard reported no differences in cholesterol absorption between estrogen-treated and untreated rabbits.
Despite the lack of effect on the plasma cholesterol levels, estrogen treatment dramatically retarded lesion development in the aortas of rabbits on the Values are means ± standard error. Number of rabbits is given in parentheses. 0.2% and 0.5% cholesterol diets. The extent of the aortic lesions was graded on a scale of 0 to 5. For the untreated animals in the two groups, the mean grade of 3.3 ± 0.3 (SE) was significantly greater than the grade of 0.8 ± 0.2 for the estrogen-treated animals. The difference in atheromatosis between the two groups was also evident from the significantly lower cholesterol content of the aortas from estrogen-treated rabbits (Table 3) .
At the end of the feeding period, we assessed the metabolic fates of cholesteryl ester in plasma, artery, and other tissues from estrogen-treated and untreated rabbits. Animals in all groups were injected with autologous plasma that had been labeled in vitro with phosphatidylcholine vesicles containing labeled cholesteryl oleate and cholesteryl oleyl ether. Labeled cholesteryl oleate, incorporated into lipoproteins by incubation at 37° C for 18 to 24 hours with phosphatidylcholine vesicles, has been shown to be representative of in vivo-incorporated labeled cholesteryl esters. 20 " 22 The use of cholesteryl ether, a nondegradable cholesteryl ester analogue, as representative of plasma cholesteryl ester is well established. 202324 The disappearance of cholesteryl ester-labeled lipoproteins from plasma was similar for the untreated and estrogen-treated animals on both diets ( Figure 3 ). Results were similar for cholesteryl ether-labeled lipoproteins.
The arterial influx of cholesteryl ester, as calculated from the influx of radioactive cholesteryl ether and expressed as nanograms of esterified cholesterol per cm 2 of aorta per hour, was significantly lower in the estrogen-treated than in the untreated rabbits ( Table 3 ). As seen in Tables 3 and 4 , there appears to be a close parallelism between the influx of cholesteryl ester (ng/cm 2 /hr) and cholesterol accumulation in the arteries of the estrogen-treated and untreated animals. A comparison of high-and lowlesioned areas within the same animal shows that influx is much greater in the high-than in the low- Values are means ± standard error. Number of rabbits is given in parentheses. 'Influx was calculated from the amount of labeled cholesteryl ether in the artery.
•.Significantly different from the untreated (p < 0.05).
Significantly different from the untreated (p < 0.01). §Significantly different from the untreated (p < 0.001). || Not significantly different from zero. ilPooled data from the two groups above.
lesioned areas (Table 4 ). If influx is expressed per unit of arterial cholesterol (nanograms of esterified cholesterol per milligram of aortic cholesterol per hour), similar values are obtained for high-and lowlesioned areas within the same animal or treated vs untreated animals within a given diet group (Tables 3  and 4 Values are means ± standard error. Number of rabbits is in parentheses. 'Significantly different from corresponding high lesioned area (p < 0.02). tSignificantly different from corresponding lesioned areas in untreated animals (p < 0.02).
Significantly different from low lesioned areas in untreated animals (p < 0.05). entered cholesteryl ester in the aorta was found to be significantly lower in the estrogen-treated than in the untreated animals ( Table 3 ). The percent hydrolysis for the treated animals on the 0.5% cholesterol diet probably represents little or no hydrolysis of cholesteryl ester in this group. Because labeled cholesteryl ester is recirculated by the liver, a small amount of labeled free cholesterol was present in the plasma by the end of the experimental period. The "negative" hydrolysis observed in some animals may be due to esterification of this labeled cholesterol by arterial tissue. In the preceding paper we showed that in vivo the atherosclerotic artery readily reesterifies the 14 Coleic acid derived from the hydrolysis of cholesteryl 14 C-oleate to available unesterified cholesterol. The percent of the labeled oleic acid released from the labeled cholesteryl ester and reesterified with cholesterol was similar for estrogen-treated and untreated rabbits.
A cursory examination of the data in Table 3 suggested that the extent of cholesteryl ester hydrolysis might be related to lesion size. To determine whether this could explain the lower hydrolysis of cholesteryl ester observed in the arteries of the estrogen-treated animals, we examined cholesteryl ester hydrolysis in high-and low-lesioned areas within the same artery for rabbits fed the 0.2% cholesterol diet. Table 4 shows that within the estrogen-treated, as well as the untreated, group, the percent hydrolysis of cholesteryl ester was similar in the low-and high-lesioned areas. Thus, comparison of the aortic arch with other arterial areas of lower cholesterol content showed that cholesteryl ester hydrolysis did not differ significantly within a treatment group. Therefore, the lower cholesteryl ester hydrolysis appears to be associated with estrogen treatment rather than lesion size.
Because arterial accumulation of cholesteryl ester depends on efflux as well as influx, the efflux of cholesteryl ether from arteries of treated and untreated animals was also measured. Autologous plasma labeled with 3 H-cholesteryl oleyl ether was injected 25 days before the final injection of autologous plasma labeled with 14 C-cholesteryl oleyl ether. The influx ratios, based upon arterial 3 H-and 14 C-cholesteryl ethers, were 0.58 ± 0.02 for the estrogen-treated and 0.54 ± 0.06 for the untreated animals. The above influx ratios demonstrate that the same fraction of newly entered cholesteryl ether was lost from both estrogen-treated and untreated rabbits.
To compare aortic tissue to other tissues known to be involved in lipoprotein catabolism, we also analyzed liver and adrenal tissue. The results for these tissues were quite different from the results seen for the artery (Table 5 ). Influx and hydrolysis of cholesteryl ester for both the liver and adrenal gland did not differ significantly for estrogen-treated and untreated rabbits. However, the hepatic esterified cholesterol content was actually significantly lower in the untreated rabbits on the 0.2% cholesterol diet than for the treated rabbits on the same diet. Although the livers from untreated rabbits on the 0.5% cholesterol diet tended to have less esterified cholesterol than the treated rabbits, the differences were not statistically significant. The ratio of 3 H-to 14 C-cholesteryl ether in the liver of estrogen-treated rabbits, on 0.2% cholesterol diet was 0.48 ± 0.04, which was significantly higher (p < 0.056) than a ratio of 0.38 ± 0.02 in the untreated rabbits. Since hydrolysis of cholesteryl ester was the same in treated and untreated livers, this indicates that a higher percentage of the newly entered cholesteryl ester was retained in the livers of the estrogen-treated animals. Since influx is Values are means ± standard error. Numbers in parentheses indicate number of rabbits. 'Significantly different from the untreated group (p < 0.05). the same in treated and untreated animals, the lower efflux of cholesteryl ester would account for the higher concentration of cholesteryl ester present in the livers of treated animals on the 0.2% cholesterol diet. The adrenals of treated and untreated animals showed the same cholesteryl ester content and the same efflux of the cholesteryl ether. The hydrolysis of cholesteryl 14 C-oleate was similar to the hydrolysis of 3 H-cholesteryl oleate in both the liver and adrenal tissue from the estrogen-treated and untreated animals.
Discussion
Despite reports that estrogens retard atherogenesis without any changes in plasma cholesterol levels 58 and that estrogens interact directly with the artery 7 " 10 ' 15~17 or with aortic smooth muscle cells, 11 -14 the belief that estrogens act strictly by lowering plasma cholesterol levels is still prevalent. Our study reports that, without significant differences in plasma cholesterol levels or lipoprotein patterns, estrogentreated animals showed significantly fewer arterial lesions than did untreated animals. These results suggest that estrogens are able to retard atherogenesis by direct interaction with the arterial wall or by altering plasma components other than lipoproteins. It is possible that lowering plasma cholesterol may enhance estrogen's effect, but our experiments indicate that plasma cholesterol lowering is not essential for a protective effect.
Before the estrogen results are discussed in detail, it is important to consider the meaning of arterial cholesteryl ester influx expressed as ng/cm 2 /hr. This quantity measures the average influx (ng cholesteryl ester/hr) into an arterial segment that contains both lesioned and nonlesioned areas. Since the influx per cm 2 of lesioned area is manyfold greater than that of the nonlesioned areas, this average does not represent the rate of influx into either the lesioned or the nonlesioned areas. The quantity ng/hr/mg arterial cholesterol, on the other hand, measures largely the influx into lesioned areas, since most of the labeled cholesterol, as well as most of the cholesterol mass, is localized in the lesioned areas. It has been shown previously 25 that influx also depends on plasma cholesterol concentration. This dependence can be removed by expressing influx as aortic clearance (nl/hr/mg). We have previously called this quantity the "relative influx." 25 As has been shown previously, the arterial influx of cholesteryl ester was roughly proportional to the arterial cholesterol content. 25 " 27 When we expressed arterial influx as aortic clearance and divided it by the arterial cholesterol content to obtain the relative cholesteryl ester influx for high-and low-lesioned areas from the same artery, as well as for arteries from estrogen-treated and untreated rabbits, we obtained approximately constant values. It seems likely, therefore, that the extent of cholesteryl ester accumulation in arterial lesions may be a direct conse-quence of the rate of cholesteryl ester influx. Therefore, factors that alter the influx of cholesteryl ester may also directly alter the accumulation of cholesteryl ester. Alternatively, the accumulation of cholesteryl ester in lesioned areas might have secondarily increased their permeability, resulting in an increased cholesteryl ester influx.
Arterial accumulation of cholesteryl ester may depend on efflux as well as influx. The cholesteryl ester taken up by arterial tissue can be deposited extracellularly or intracellularly. Efflux of cholesteryl ester can occur from the extracellular space or, after hydrolysis, from intracellular sites. 28 The efflux of cholesteryl ether from the artery probably represents efflux of extracellular sterol, since cholesteryl ether is not hydrolyzed by tissues. We found that estrogen administration did not alter cholesteryl ether efflux and, therefore, probably did not change extracellular cholesteryl ester efflux. Efflux of intracellular cholesteryl ester can be affected by the extent of hydrolysis of cholesteryl ester as well as by the extent of reesterification. In the present study, estrogen administration did not alter the re-esterification of labeled oleic acid to cholesterol. Therefore, if efflux of cholesteryl ester plays a role in the mode of action of estrogen in retarding atherogenesis, increased hydrolysis would be expected. Surprisingly, in the present in vivo study, the percentage of newly entered cholesteryl ester hydrolyzed was significantly less in arteries from estrogen-treated rabbits than in those from untreated rabbits. The possibility that the lower hydrolysis may have been due to the lower lesion size in the estrogen-treated rabbits was eliminated when we compared low-and high-lesioned areas of arteries within estrogen-treated and untreated animals. Since cholesteryl ester hydrolysis was actually lower and re-esterification and extracellular efflux did not differ between estrogen-treated and untreated animals, estrogen does not appear to retard atherogenesis by increasing the efflux of cholesterol from arterial tissue.
The lower hydrolysis of cholesteryl ester in the estrogen-treated animals could have resulted from the failure of cholesteryl ester to reach the enzyme site or from a much lower enzyme activity. However, a decrease in enzyme activity would more likely lead to an increase in the accumulation of cholesteryl ester rather than a decrease. Also, it has been shown that cholesteryl ester hydrolase activity does not appear to be limiting in atherogenesis 29 and that its activity, when measured in vitro, is unchanged or increased after estrogen administration. 730 It seems reasonable to assume that the hydrolysis of cholesteryl ester takes place mostly intracellularly. 31 We have also reported that the percentage of cholesteryl ester hydrolyzed by arterial tissue does not parallel the experimental period, but appears to be independent of time. 20 Therefore, it is suggested that in the artery the percentage of cholesteryl ester hydrolyzed is indicative of the cellular uptake of cholesteryl ester. The low cholesteryl ester hydrolysis seen in estrogentreated animals may therefore be due to a decrease in the fraction of cholesteryl ester influx directed to intracellular sites. The suggestion that estrogen lowers cellular cholesteryl ester uptake parallels the findings by Leake et al. 32 that some agents that retard atherogenesis decrease pinocytosis in cultured arterial smooth muscle cells, and that some agents that are thought to play a role in the development of atherosclerosis increase pinocytosis. If estrogen slows accumulation of arterial cholesteryl ester by reducing uptake of cholesteryl ester into cells which have the potential of becoming foam cells, then this would explain the retardation of atherogenesis in the estrogen-treated animals.
